This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human Coagulation Factor II / Thrombin Protein, His Tag
catalog :
THN-H52H0
quantity :
50 ug, 500 ug
price :
350 USD, 1200 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
THN-H52H0
product name :
Human Coagulation Factor II / Thrombin Protein, His Tag
quantity :
50 ug, 500 ug
price :
350 USD, 1200 USD
quantity & price :
$350/50ug,$1200/500ug
target :
Coagulation Factor II
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human Coagulation Factor II, His Tag (THN-H52H0) is expressed from human 293 cells (HEK293). It contains AA Gln 25 - Glu 622 (Accession # AAH51332).
SDS-PAGE Remark(R&NR) :
Human Coagulation Factor II, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than .
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Prothrombin is also known as coagulation factor II (F2),which can be cleaved into the following 4 chains: activation peptide fragment 1, activation peptide fragment 2, thrombin light chain and thrombin heavy chain. Coagulation factor II (F2) is able to form a heterodimer with SERPINA5. The mutations of F2 gene can result in a very rare blood coagulation disorder characterized by mucocutaneous bleeding symptoms. Furthermore, thrombin converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Coagulation factor II (F2) can also play an important role in blood homeostasis, inflammation and wound healing.
References :
(1) Degen S.J.F., et al., 1983, Biochemistry 22:2087-2097.
(2) Butkowski R.J., et al., 1977, J. Biol. Chem. 252:4942-4957.
(3) Fife C., et al., 2007, Wound Repair Regen. 15:23-34.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments